- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03421236
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Escalating doses of Ty21a/Vivotif® will be administered by the intravesical route to evaluate whether Ty21 may replace the standard BCG immunotherapy in NMIBC patients.
The minimal starting dose will be instilled intravesically once a week for 4 weeks in 3 patients. If well tolerated, a 5-fold higher dose will be instilled 4-times in 3 other patients, and so on for a maximum of 4 doses to be tested.
The maximal tolerated dose will then be administered to 3 new patients 6-times once a week. If 6 instillations are well tolerated, 7 additional patients will be included to receive 6 instillations with this maximal tolerated dose.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: denise N Haefliger, PhD
- Phone Number: +41213144081
- Email: dnardell@hospvd.ch
Study Contact Backup
- Name: Denise N Haefliger, PhD
- Phone Number: 0213144081
- Email: dnardell@hospvd.ch
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Recruiting
- Dpt Urology- CHUV
-
Contact:
- denise N Haefliger
- Phone Number: 213144081
- Email: dnardell@hospvd.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with an intermediary or low risk of progression of bladder cancer (according to an EORTC score and clinical considerations) and thus not requiring BCG immunotherapy will be included after a transurethral resection of the bladder tumor (TURBT). Male and Female patients aged > 18yrs, with a Karnofsky performance status of 60% or more, sero-negative for HIV, HBV and HCV and with laboratory parameters for vital function in the normal range or with abnormalities without clinical significance may be included.
Exclusion Criteria:
- Patients with NMIBC that require BCG treatments or with muscle-invasive bladder cancer, sero-positive for HIV, HBV and HCV or with other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders, autoimmune disease), will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: non muscle invasive bladder cancer patient
intravesical instillation of Ty21a in patients not requiring BCG
|
intravesical administration of Ty21a
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 6 weeks
|
safety and tolerability of intravesical Ty21a
|
6 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IvesTy21a
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Muscle Invasive Bladder Cancer
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Ractigen Therapeutics.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)Australia
-
Janssen Research & Development, LLCNot yet recruitingNon-Muscle Invasive Bladder CancerCzechia
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingHigh-risk Non-muscle Invasive Bladder CancerChina
-
Johns Hopkins UniversityRecruitingNon-Muscle Invasive Bladder CancerUnited States
-
Binhui Biopharmaceutical Co., Ltd.RecruitingNon-muscle-invasive Bladder CancerChina
-
ImmunityBio, Inc.Active, not recruitingNon Muscle Invasive Bladder CancerUnited States
Clinical Trials on Ty21a
-
USDA, Western Human Nutrition Research CenterUniversity of MinnesotaRecruitingInflammation | Typhoid Fever | Vaccine | Intestinal PermeabilityUnited States
-
University of Maryland, BaltimoreActive, not recruitingTyphoid VaccinationUnited States
-
University of OxfordUniversity of Maryland; Imperial College London; Wellcome TrustCompletedTyphoid Fever | Typhoid | Enteric FeverUnited Kingdom
-
University of Maryland, BaltimoreRecruitingTyphoid and/or Cholera VaccinationUnited States
-
Haukeland University HospitalHelse VestTerminated
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHepatitis A | Influenza | Healthy Adults | TyphoidUnited States
-
USDA, Western Human Nutrition Research CenterActive, not recruitingInflammation | Typhoid Fever | Vaccine | Intestinal PermeabilityUnited States